On the call today are Ming Hsieh, chief executive officer; Paul Kim, chief financial officer; Dr. Larry Weiss, chief medical officer; Brandon Perthuis, chief commercial officer. The company's press release discussing its financial results is available in the investor relations section of the company's website, fulgentgenetics.com.
In this segment of "Backstage Pass" on Motley Fool Live, recorded on July 27, Fool.com contributors Matt Frankel and Jason Hall discuss some of the reasons why it could be a good time to invest in the business. Matt Frankel: So Jason, why don't you give us a quick overview of Fulgent and why you doubled down on it or however much you added? This is a company that's very much grouped in with the COVID stocks, so Ming Hsieh, the founder of the company, has a long history of success as an entrepreneur.
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 6.85% and 2.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?